Growth hormone pathway peptides: what readers should understand
How tesamorelin, sermorelin, CJC-1295, and ipamorelin differ in mechanism, status, and evidence.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
The quick overview
These peptides can influence the growth-hormone pathway in different ways, but a shared pathway does not give them shared approval, evidence, or safety.
Tesamorelin has a narrow FDA-approved HIV-lipodystrophy indication. Sermorelin's former approved product is discontinued. CJC-1295 and ipamorelin are not FDA approved and have limited evidence for popular consumer uses.
Side-by-side comparison
| Peptide | Status | Evidence | Studied for |
|---|---|---|---|
| Tesamorelin | FDA approved for specific uses | Strong human evidence for approved uses | HIV-associated lipodystrophy; Visceral abdominal fat; Metabolic measures |
| Sermorelin | Discontinued | Limited or unclear evidence | Growth hormone secretion testing; Growth hormone deficiency in historical contexts; Growth hormone pathway effects |
| CJC-1295 | Not FDA approved | Early human evidence | Growth hormone and IGF-1 levels; Pharmacology and tolerability |
| Ipamorelin | Not FDA approved | Early human evidence | Growth hormone release; Gastrointestinal motility; Postoperative ileus |
Studied for
HIV-associated lipodystrophy · Visceral abdominal fat · Metabolic measures
Studied for
Growth hormone secretion testing · Growth hormone deficiency in historical contexts · Growth hormone pathway effects
Studied for
Growth hormone and IGF-1 levels · Pharmacology and tolerability
Studied for
Growth hormone release · Gastrointestinal motility · Postoperative ileus
Approved versus investigational
An FDA approval means the agency reviewed evidence for a specific product, population, and use. It does not validate other molecules in the same family or uses outside the label. “In Phase 3” still means investigational.
What researchers are studying
- Growth hormone and IGF-1 signaling
- HIV-associated lipodystrophy
- Historical diagnostic testing
- Body composition and gastrointestinal research
Risks and reasons for caution
- Growth hormone and IGF-1 affect many tissues; more signaling is not automatically better.
- Blood-sugar changes, fluid retention, joint symptoms, and other pathway-related risks may matter.
- Past approval, a narrow approval, and no approval are three different regulatory states.
What remains uncertain
- Long-term safety for unapproved wellness uses
- Whether hormone-level changes produce meaningful functional outcomes
- Safety and effectiveness of combinations promoted online
Questions to ask a healthcare professional
1. Is there a diagnosed condition and an approved option?
2. Is the goal a laboratory number or a meaningful health outcome?
3. What conditions make growth-pathway stimulation risky?
4. Is the claimed product covered by an approved application?
Plain-English takeaway
Pathway similarity is not clinical equivalence. Tesamorelin's narrow approval does not validate sermorelin, CJC-1295, ipamorelin, or their combinations for anti-aging or body-composition claims.
References
- 1FDA: Drugs@FDA database
Official source for approval records and current prescribing information.
- 2FDA: understanding the risks of compounded drugs
FDA overview of how compounded drugs differ from FDA-approved drugs.
- 3PubMed
Peer-reviewed biomedical literature indexed by the National Library of Medicine.